Sources
Loading...
Additional media
Loading...
DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
US lawmakers are seeking a briefing on a biotech firm's ties to China amid escalating tensions. Experts suggest that the recent crackdown on Chinese biotech companies is a protectionist move that could hinder US technological competitiveness in the medical sector. The Biosecure Act, currently just a proposal and not yet a law, is already having a chilling effect on biotech relationships, as observed at the BIO2024 conference. There is also a national security issue that needs to be addressed, and the Biosecure Act could face significant problems.
At BIO, signs Congress’ tough stance on China is chilling biotech relationships https://t.co/aTaXQRPpBd via @JonathanWosen @megkesh
The BIOSECURE act is for now just a proposal, not a law. But at #BIO2024,@megkesh and I found that Congress' tough stance on China is already chilling biotech relationships. Our story for @statnews https://t.co/irSrHEEnWN
The BIOSECURE act is for now just a proposal, not a law. But at #BIO2024, @megkesh and I found that Congress' tough stance on China is already chilling biotech relationships https://t.co/irSrHEEnWN
